Allergic Rhinitis: Current and Emerging Therapies to Optimize Patient Outcomes—Strategies for Allergy Specialists

Program Description:

In patients with prolonged symptoms of allergic rhinitis (AR), inadequate symptom control, intolerance to medication, complications of AR and/or comorbid asthma or rhinosinusitis, or the need to identify the allergens causing the symptoms, consultation with the allergy specialist is imperative. By identifying the factors that trigger the AR symptoms and selecting appropriate therapy from current and emerging treatment options, as well as providing patient education, the allergist can help optimize patient outcomes in AR. The case study interwoven throughout this online monograph illustrates the approach to a patient referred from primary care to the allergy specialist for allergen detection and management following treatment failure.

INTENDED AUDIENCE:

Allergists, immunologists, otolaryngic allergists, and ear, nose and throat physicians who care for allergy patients

Activity Objectives:

Upon completion of this educational activity, clinicians should be better able to:

• Identify factors triggering allergic rhinitis symptoms.


• Select the most appropriate therapeutic agents for individual patients, considering current and emerging therapies.


• Provide patient education to enhance clinical outcomes.

Faculty:

CHAIR
Warner W. Carr, MD, FAAAAI, FACAAI, FACP
Associate Medical Director
Allergy & Asthma Associates of Southern California
Southern California Research
Mission Viejo, California

FACULTY
Charles J. Siegel, MD
Allergy & Asthma Specialists of Kansas City
Gladstone, Missouri

CME COURSE REVIEWER
David L. Rosenstreich, MD
Professor, Department of Medicine (Allergy & Immunology)
Albert Einstein College of Medicine of Yeshiva University
Bronx, New York

Disclosures:

Conflict of Interest Disclosure Statement
The “Conflict of Interest Disclosure Policy” of Albert Einstein College of Medicine of Yeshiva University requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest with regard to their contribution to the activity will not be permitted to present.

Warner W. Carr, MD, FAAAAI, FACAAI, FACP, has received grant/research from Meda Pharmaceuticals, Inc., Alcon Laboratories, Inc., and ISTA Pharmaceuticals, Inc. He is a consultant for Meda Pharmaceuticals, Inc., Alcon Laboratories, Inc., ISTA Pharmaceuticals, Inc., and Sunovion Pharmaceuticals Inc. Dr. Carr is also on the speakers’ bureaus for Meda Pharmaceuticals, Inc., Alcon Laboratories, Inc., ISTA Pharmaceuticals, Inc., GlaxoSmithKline, Merck & Co., Inc.

Charles J. Siegel, MD, is a consultant for Meda Pharmaceuticals, Inc., and Teva Pharmaceuticals USA. He is also on the speakers’ bureaus for Meda Pharmaceuticals, Inc., Merck & Co., Inc./Schering, and Teva Pharmaceuticals USA.

David L. Rosenstreich, MD, has nothing to disclose with regard to commercial support.

Publishing Staff
Mary Jo Krey, Eileen McCaffrey, and Sharon Hill-Ingram of Haymarket Medical Education have nothing to disclose with regard to commercial support.

Accreditor Staff
The staff of the Center for Continuing Medical Education of Albert Einstein College of Medicine of Yeshiva University has nothing to disclose with regard to commercial support.

Disclosure of Unlabeled Use
This educational activity may contain discussion of approved and/or investigational uses of agents that are not indicated by the FDA. Albert Einstein College of Medicine of Yeshiva University, Meda Pharmaceuticals, Inc., and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Albert Einstein College of Medicine of Yeshiva University, Meda Pharmaceuticals, Inc., and Haymarket Medical Education. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Privacy Policy
To view the myCME privacy policy, please click here.

To view the privacy policy for Albert Einstein College of Medicine of Yeshiva University, please click here.

Accredited Provider:

This program is sponsored by Albert Einstein College of Medicine of Yeshiva University.

Commercial Supporter:

This program is supported by an educational grant from Meda Pharmaceuticals, Inc.

Instructions:

To obtain credit, a score of 70% or better is required. This CE is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the posttest survey, and have received your digital copy of your credit certificate. Your online certificate will be saved on myCME.com within your Profile/Exam History, which you can then access at any time.

If you have any questions relating to the accreditation of this activity, please contact Mildred Shields Adighiuzor, Associate Director, Albert Einstein College of Medicine, CME Marketing at (718) 920-6674.

If you have any questions relating to your certificate or other issues with this activity, please contact myCME.Support@haymarketmedical.com.

SYSTEM REQUIREMENTS:

WINDOWS PC SYSTEM REQUIREMENTS:
266-MHz Pentium II; Windows 98 or higher; 64 MB RAM; 800 x 600 screen resolution set for “High Color (16-Bit)”; Macromedia Flash Player 6 or higher.

MACINTOSH^® SYSTEM REQUIREMENTS:
Power Mac g3 at 300 MHz; System 8.5 or higher (excluding Mac OSX); 96 MB RAM; 20 MB minimum hard disk space available; 800 x 600 screen resolution set to “Thousands of Colors”; Macromedia Flash Player 6 or higher.